PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
2.40%
Revenue growth of 2.40% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
3.40%
Gross profit growth of 3.40% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
-2.91%
Negative EBIT growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
4.04%
Positive operating income growth while Medical - Pharmaceuticals is negative. Peter Lynch would spot a big relative advantage here.
-15.54%
Negative net income growth while Medical - Pharmaceuticals median is -0.51%. Seth Klarman would investigate factors dragging net income down.
-15.54%
Negative EPS growth while Medical - Pharmaceuticals median is -0.30%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-15.54%
Negative diluted EPS growth while Medical - Pharmaceuticals median is -0.30%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
0.00%
Share reduction exceeding 1.5x Medical - Pharmaceuticals median of 0.14%. Joel Greenblatt would applaud significant buybacks if they are value-accretive.
0.00%
Diluted share reduction exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt would see a meaningful advantage if shares are undervalued.
-100.00%
Dividend cuts while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others maintain or grow payouts, highlighting a relative weakness.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
59.57%
10Y revenue/share CAGR 1.25-1.5x Medical - Pharmaceuticals median of 46.81%. Mohnish Pabrai would see if consistent reinvestment or product expansions drive this gap.
57.04%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 20.86%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
29.96%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 14.80%. Joel Greenblatt might see a short-term competitive advantage at play.
-100.00%
Negative 10Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
86.45%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 3.55% over a decade. Joel Greenblatt might see a standout compounder of earnings.
86.04%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 3.51%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
9.43%
3Y net income/share CAGR of 9.43% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a small advantage that can be scaled further.
No Data
No Data available this quarter, please select a different quarter.
130.07%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 48.95%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
62.57%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 14.82%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
-100.00%
Dividend declines over 10 years while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a relative disadvantage if peers consistently raised payouts.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-39.20%
AR shrinking while Medical - Pharmaceuticals median grows. Seth Klarman sees potential advantage unless it signals declining demand.
-3.35%
Decreasing inventory while Medical - Pharmaceuticals is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
0.06%
Below 50% of Medical - Pharmaceuticals median. Jim Chanos suspects stagnation or limited capital availability for expansions.
3.14%
Positive BV/share change while Medical - Pharmaceuticals median is negative. Peter Lynch finds a strong advantage vs. peers failing to expand equity.
-41.08%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
96.39%
SG&A growth far above Medical - Pharmaceuticals median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.